Drugs / Vacc-4x
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT02998996 | Sep 2016 → Jun 2017 | influenza | Eurocine Vaccines AB | Completed | No outcome recorded |
| Phase 1/2 | NCT02092116 | Mar 2014 → Aug 2015 | HIV infectious disease | Bionor Immuno AS | Completed | No outcome recorded |
| Phase 1/2 | NCT01704781 | Sep 2012 → Aug 2014 | HIV infectious disease | Bionor Immuno AS | Completed | No outcome recorded |
| Phase 1/2 | NCT01473810 | Nov 2011 → Mar 2012 | HIV infectious disease | Oslo University Hospital | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01712256 | Dec 2012 → Jan 2014 | HIV infectious disease | Bionor Immuno AS | Completed | No outcome recorded |
| Phase 2 | NCT00659789 | Aug 2008 → Jun 2010 | HIV infectious disease | Bionor Immuno AS | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vacc-4x | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00659789 ↗ |
| Known as | Endocine | “in conjunction with Endocine, a newly developed and documented mucosal adjuvant” NCT01473810 ↗ |
| Modality | Peptide | “Vacc-4x is a peptide-based HIV immunotherapy” NCT00659789 ↗ |
| Route | Intranasal | “Intranasal administration of a therapeutic HIV vaccine (Vacc-4x)” PMID 25398137 ↗ Nov 2014 |